Background—Patients with recovery of left ventricular ejection fraction (LVEF) remain at risk
for future deterioration of LVEF. However, there are no tools to risk stratify these patients. We …

Heart failure (HF) is a highly prevalent clinical syndrome characterized by considerable
phenotypic heterogeneity. The traditional classification based on left ventricular ejection …

Background: Left ventricular ejection fraction (LVEF) is calculated from volumetric change
without representing true myocardial properties. Strain echocardiography has been used to …

In terms of sacubitril/valsartan (S/V)-induced changes in heart failure with reduced ejection
fraction (HFrEF) via three-dimensional (3D) transthoracic echocardiography (TTE) and S/V …

Background Left ventricular (LV) systolic strain is presumably a more sensitive myocardial
indicator than LV ejection fraction (LVEF). Data regarding the use of LV strain in clinical risk …

Background Compared to angiotensin inhibition, angiotensin-neprilysin “blockade”
improves mortality and reduces hospitalizations in patients with heart failure (HF) with …

Increased vascular stiffness is known to be an independent predictor of mortality in patients
with heart failure with reduced ejection fraction (HFrEF). The effects of sacubitril–valsartan …

Background—Impairment in left ventricular systolic function has been described in heart
failure (HF) with preserved ejection fraction (HFpEF), but its prognostic relevance is not …

Background The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V)
improves cardiovascular outcomes in heart failure with reduced ejection fraction (HFrEF) …

Heart failure (HF) represents a widespread health problem characterized by high morbidity
and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients …